• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Gilead Sciences

Fauci: Hundreds of millions of COVID-19 vaccine doses could be ready in January

April 30, 2020 By Nancy Crotti

coronavirus COVID-19

Dr. Anthony Fauci said this morning that hundreds of millions of doses of a vaccine for COVID-19 could be ready by January. In an interview on the Today Show, the director of the National Institute of Allergy and Infectious Diseases said that a vaccine candidate is in the first phase of a clinical trial. If the second […]

Filed Under: Business/Financial News, Clinical Trials, Hospital Care Tagged With: coronavirus, COVID-19, Gilead Sciences, National Institutes of Health

Here are the pharma companies accused of blocking generic competition

May 17, 2018 By Sarah Faulkner

Pills

To prove a generic drug is as safe and effective as the branded version, pharmaceutical companies have to hand over upwards of 1,000 doses of the product to a generic developer. But if the manufacturer creating the generic drug cannot get its hands on enough sample, the development and testing process slows down. It could […]

Filed Under: Featured, Food & Drug Administration (FDA), Pharmaceuticals, Wall Street Beat Tagged With: Actelion Pharmaceuticals, Celgene, FDA, Gilead Sciences, GlaxoSmithKline plc, Johnson & Johnson, Novartis, Valeant Pharmaceuticals

Gilead inks $90m deal with Verily to create “molecular map” of inflammatory disease

May 1, 2018 By Sarah Faulkner

Gilead Sciences (NSDQ:GILD) is reportedly slated to pay Alphabet’s Verily Life Sciences $90 million over three years to analyze cells from patients with rheumatoid arthritis, inflammatory bowel disease and lupus-related diseases. By probing immune cells from patients involved in Gilead’s clinical trials, the companies hope to glean a better understanding of the immunological signatures of RA, […]

Filed Under: Clinical Trials, Diagnostics, Discovery, Drug-Device Combinations, Featured, Immunotherapy, Pharmaceuticals, Wall Street Beat Tagged With: Gilead Sciences, Verily

NIH launches first large-scale trial of long-acting injectable HIV prevention drug

November 30, 2017 By Sarah Faulkner

Long-acting HIV drug

The National Institutes of Health said today that it has launched the first large-scale clinical trial of a long-acting injectable drug for HIV preparation in sexually-active women. The NIH is funding the study in partnership with ViiV Healthcare and the Bill & Melinda Gates Foundation. The study, which is being conducted in southern and eastern […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: Gilead Sciences, National Institutes of Health, viivhealthcare

This company helps cell therapies travel around the world

October 19, 2017 By Sarah Faulkner

Cryoport

With Gilead Sciences (NSDQ:GILD) and Novartis (NYSE:NVS) leading the way, cell therapies are moving on to the market and into the clinics for patients that have no other option. Companies making CAR-T therapies use a patient’s own cells to genetically engineer a cancer-killing cellular therapy that is then delivered back to the patient. And one 55-person company […]

Filed Under: Featured, Pharmaceuticals, Wall Street Beat Tagged With: cryoport, Gilead Sciences, kitepharma, Novartis

Kite wins FDA approval for first adult CAR-T cell therapy

October 19, 2017 By Sarah Faulkner

More than a month before it was due to make a decision, the FDA yesterday approved a CAR-T cell therapy from Kite Pharma (NSDQ:KITE) – the first of its kind for adults. The therapy, which is made from a patient’s own cells, is designed to treat adults with non-Hodgkin lymphoma who have failed at least two […]

Filed Under: Featured, Food & Drug Administration (FDA), Oncology, Pharmaceuticals, Wall Street Beat Tagged With: Gilead Sciences, kitepharma, Novartis

How etectRx’s “smart pill” aims to improve patient compliance trends

October 17, 2017 By Sarah Faulkner

etectRx

When Harry Travis first met Neil Euliano and learned about his medication adherence technology, the pharmaceutical industry was beginning to usher in the age of pricey drugs with Hepatitis C therapies that hit the market at prices like $500 or $1,000 dollars a pill. “It just so happened at the time, really expensive medications were […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Technology Tagged With: Brigham & Women's Hospital, etectrx, Gilead Sciences

Gilead expands into cell therapy with $11.9B Kite Pharma purchase

August 28, 2017 By Sarah Faulkner

Taking a plunge into the cell therapy arena, Gilead Sciences (NSDQ:GILD) said today that it has inked an $11.9 billion deal to acquire Kite Pharma (NSDQ:KITE). The deal, which was unanimously approved by both companies’ boards, is slated to close in the fourth quarter of this year. Gilead said it plans to pay $180 in cash […]

Filed Under: Business/Financial News, Featured, Immunotherapy, Mergers & Acquisitions, Pharmaceuticals, Wall Street Beat Tagged With: Gilead Sciences, kitepharma

Leukemia trial to match patients with drugs based on genetic biomarkers

July 19, 2017 By Sarah Faulkner

Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society said today that its expanding its Beat AML Master trial to include five investigational treatments for acute myeloid leukemia. The trial, which launched in October last year, has enrolled 70 patients and has garnered support by Alexion Pharmaceuticals (NSDQ:ALXN), Boehringer Ingelheim, Celgene (NSDQ:CELG) and Gilead Sciences (NSDQ:GILD), all of which are providing investigational […]

Filed Under: Clinical Trials, Featured, Oncology, Pharmaceuticals, Wall Street Beat Tagged With: alexionpharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Celgene, Gilead Sciences

Senate drug price hearing turns into debate over healthcare reform

June 19, 2017 By Sarah Faulkner

Prescription drugs

Members of the Senate Health, Education, Labor and Pensions committee gathered last week to discuss the rising costs of prescription drugs. But the hearing quickly morphed into a heated back-and-forth between senators over the Republican’s efforts to reform healthcare. Democratic senators, including Sens. Patty Murray (D-Wash.) and Chris Murphy (D-Conn.), used their time to criticize […]

Filed Under: Featured, Food & Drug Administration (FDA), Pharmaceuticals, Policy, Wall Street Beat Tagged With: Capitol Hill, Gilead Sciences

  • Go to page 1
  • Go to page 2
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by DrugDeliveryNow

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS